Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (27,631)	$ (69,200)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	587	442
Gain on disposal of equipment	(70)	(75)
Noncash interest expense	0	35
Share-based compensation	4,305	2,843
Amortization of premium and discount on marketable securities	(190)	0
Write-off of in-process R&D	0	50,618
ROU asset amortization	833	786
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	639	63
Accounts payable	1,894	(193)
Accrued expenses	(3,033)	427
Operating lease liability	(818)	(747)
Net cash used in operating activities	(23,484)	(15,001)
Cash flows from investing activities:
Purchases of property and equipment	(158)	(791)
Purchases of marketable securities	(117,332)	0
Proceeds from sale or maturities of marketable securities	12,760	0
Asset acquisition costs	0	(318)
Proceeds from sale of equipment	176	115
Net cash used in investing activities	(104,554)	(994)
Cash flows from financing activities:
Proceeds from issuance of common stock	5	0
Repayment of borrowings under loan	0	(5,625)
Net cash provided by (used in) financing activities	5	(5,625)
Net change in cash, cash equivalents and restricted cash	(128,033)	(21,620)
Cash, cash equivalents and restricted cash at beginning of period	144,514	47,339
Cash, cash equivalents and restricted cash at end of period	16,481	25,719
Supplemental disclosure of cash flow information
Cash paid for interest	0	226
ROU asset acquired through operating leases	0	5,148
Unrealized loss on marketable securities	641	0
Acquisition of Trigr Therapeutics, Inc.	$ 0	$ 50,300